Результаты поиска

Clinical outcomes and prognostic factors in advanced high-grade platinum-resistant ovarian carcinoma: evidence from the ESME real-world cancer database.

OBJECTIVE: We aimed to describe real-world outcomes of chemotherapy with or without bevacizumab in patients with platinum-resistant high-gra … differences, chemotherapy-alone and chemotherapy-plus-bevacizumab groups were analyzed separately. Progression-free survival and overall survival were estimated using Kaplan-Meier methods and multi-variable Cox models. RESULTS: A total of 688 patients were included: 580 (84.3%) received chemotherapy alone and 108 (15.7%) chemotherapy plus bevacizumab. Median progression- …

CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials.

BACKGROUND: CDK4/6 inhibitors have shown clinical benefits in patients with hormone receptor-positive, HER2-negative advanced breast cancer. … roup performance status, bone-only disease, and visceral metastasis. Primary outcomes analysed were progression-free survival and overall survival. The protocol is registered in PROSPERO (CRD420251073444). FINDINGS: 11 phase 3 trials, including 6035 patients and four agents-abemaciclib, ribociclib, palbociclib, and dalpiciclib-were included. CDK4/6 inhibitors plus endocri …

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.

OBJECTIVE: Anlotinib, an oral small-molecular tyrosine kinase inhibitor (TKI) on tumor angiogenesis and growth, has a wide spectrum of inhib … response, survival outcomes, and safety. RESULTS: A total of 38 patients were analyzed. The median progression-free survival and the median overall survival were 7.7 months (95% CI: 6.7-8.7) and 16.5 months (95% CI: 13.3-19.7), respectively. About 17 patients received anlotinib monotherapy, and the median progression-free survival was 7.7 months (95% CI: 6.3-9.1). A total …

CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.

BACKGROUND: CD69 is expressed in several hemopoietic cells and is an early activation marker in chronic lymphocytic leukemia. Chronic lymphocytic leukemia is a clinically heterogeneous disease which needs novel prognostic parameters which can be easily and efficiently managed. DESIGN AND METHODS: We investigated CD69 by flow cytometry in a series of 417 patients affected by chronic lymphocytic leukemia and compared this to other biological and clinical prognosticators. RESULTS: CD69 was associated with Rai stages (P=0.00002), β(2)-microglobulin (P=0.0005) and soluble CD23 (P<0.0001). CD69 an

Long-Term Results of Autologous Hematopoietic Cell Transplantation (Auto-HCT)-Real-Life Data of 15- and 20-Year Survivals From a Single Center.

Over the years, autologous hematopoietic cell transplantation (auto-HCT) has become one of the most important therapeutic methods of contemporary hematology. However, analyses of survival after treatment are usually limited to 5-10 years. Data on longer survival are limited due to difficulties and loss in follow-up, as well as organizational and personnel changes in transplant centers. Therefore, our study aimed to evaluate the 15- and 20-year overall and progression-free survival of the recipients of auto-HCT in our center without exclusion of salvage indications and patients with comorbiditi…

Prognostic factors in patients undergoing lymphadenectomy for squamous cell carcinoma of the penis.

INTRODUCTION: Penile cancer is rare, and data on prognostic factors of the disease are scarce. The aim of the study was to assess prognostic factors in patients undergoing lymphadenectomy for penile cancer. MATERIAL AND METHODS: Ninety-eight men who underwent lymphadenectomy for penile cancer were enrolled in the study. Progression-free survival and overall survival were assessed. RESULTS: Five-year progression-free survival and overall survival were 0.6651 (95% CI: 0.5151-0.7783) and 0.5516 (95% CI: 0.4412-0.6488), respectively. Multivariate analysis showed that the factors that reduce prog…

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on the Use of Primary Chemoimmunotherapy to Treat Patients with Locally Advanced or Recurrent Endometrial Cancer.

The publication of two large randomized studies - the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial and the NRG-GY018 trial - which investigated combi … py with carboplatin and paclitaxel resulted in a significant and clinically relevant improvement of progression-free survival and overall survival in the overall population, a significant and clinically relevant improvement of progression-free survival and overall survival in the subgroup with dMMR/MSI-high tumors, and a significant and clinically relevant improvement of p …

Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy.

In recent years, minimal residual disease (MRD) testing has emerged as a powerful prognostic tool in multiple myeloma. Multiple meta-analyses have demonstrated that achieving MRD negativity is associated with significantly improved progression-free survival (PFS), leading to its acceptance as a surrogate endpoint in clinical trials to support accelerated drug approval. Looking forward, MRD status is poised to be incorporated into treatment decision-making; to guide escalation and de-escalation of therapy with the aims of improved progression free survival with limited treatment toxicity. In th…

Small- and medium-sized hepatocellular carcinomas: monopolar radiofrequency ablation with a multiple-electrode switching system-mid-term results.

PURPOSE: To prospectively assess the safety and mid-term therapeutic effectiveness of monopolar radiofrequency (RF) ablation with a multiple … en every 3 months after the procedure. The overall survival, disease-free survival, and local tumor progression-free survival rates were evaluated by using the Kaplan-Meier method. RESULTS: The technique effectiveness rate determined 1 month after RF ablation was 99.4%. Mean ablation parameters were as follows: volume, 85 cm(3) ± 54; maximum diameter, 61 mm ± 13; and mini …

Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World.

AIM: This retrospective observational study evaluated the role of hypo-fractionated stereotactic radiotherapy (SRT) in patients with oligo-p … nated SRT to progressive metastatic sites to delay the change of systemic therapy. First and second progression-free survival (PFS-1 and PFS-2) were recorded, as well as objective response and toxicity. RESULTS: After pazopanib therapy, nine partial remissions (32%), 12 stable disease (43%) and seven progressions (25%) were recorded. The median time to progression from fi …

Эффективность и надежность аутологической трансплантации стволовых клеток после химиотерапии при лечении злокачественной лимфомы: метаанализ.

: Автономная трансплантация стволовых клеток (AHSCT) является ценным средством лечения нескольких гематологических заболеваний, особенно в случаях рецидива или рецидива. Автономная трансплантация стволовых клеток (AHSCT) помогает улучшить показатели выживаемости отдельных пациентов, особенно больных с агрессивной лимфомой и множественной миеломой. Исследования показывают, что AHSCT может превзойти альтернативную терапию, но текущие исследования необходимы для совершенствования отбора пациентов. Многие пациенты страдают от продолжительной ремиссии и более высокого качества жизни, что свидетельс

Совпадение в аннотации оригинала
BACKGROUND: Autologous hematopoietic stem cell transplantation (AHSCT) is a valuable treatment option for several hematological malignancies … andard chemotherapy (with no restrictions on the chemotherapy regimen). The outcome indicators were progression-free survival (PFS), complete remission rate (complete response (CR) + partial response (PR)), and overall survival (OS). RESULTS: Fifteen literature pieces in all, consisting of 1229 subjects in the control group and 896 subjects in the experimental group, were …

T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.

BACKGROUND: Chimeric antigen receptor T cells and bispecific antibodies, are moving from late-line salvage into early relapsed multiple myel … raph-theoretical model. Control-arm dispersion was quantified by random-effects synthesis of median progression-free survival. Overall survival was additionally analyzed as restricted mean survival differences at 24 and 36 months. Safety and a cost-consequence analysis were assessed descriptively (PROSPERO: CRD420261431847). RESULTS: Four trials (2,174 patients) investiga …

A cross-sectional study of the association of dental health factors with progression and all-cause mortality in men diagnosed with HPV-associated oropharyngeal cancer.

BACKGROUND: Human Papillomavirus-associated oropharyngeal cancer (HPV-OPC) incidence is increasing among men in the United States. Poor dent … uted. Cox proportional hazards model was used to assess whether dental factors were associated with progression-free survival or overall mortality. RESULTS: Among 206 HPV-OPC cases, median follow-up was 3.4 years (IQR: 2.4-4.4) during which 40 cases involved progression or mortality and 25 deaths occurred. Overall dentition was significantly associated with progression fr …

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

BACKGROUND: Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are a … hysician's choice of enzalutamide or abiraterone (control). The primary end point was imaging-based progression-free survival in cohort A according to blinded independent central review. RESULTS: In cohort A, imaging-based progression-free survival was significantly longer in the olaparib group than in the control group (median, 7.4 months vs. 3.6 months; hazard ratio for …

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

BACKGROUND: An interim analysis of progression-free survival in this trial showed that ibrutinib-venetoclax was superior to fludarabine-cyclophosphamide-rituximab (FCR) among patients with chronic lymphocytic leukemia (CLL). Whether ibrutinib-venetoclax is more effective than ibrutinib alone is unclear. METHODS: In this phase 3, multicenter, open-label trial, we randomly assigned patients with CLL to receive ibrutinib-venetoclax, ibrutinib alone, or FCR. The primary end points were undetectable measurable residual disease (MRD) in bone marrow within 2 years in the ibrutinib-venetoclax group a…

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.

BACKGROUND: Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of th … uction low minimal residual disease (<10(-4) cells) continued chemotherapy. The primary outcome was progression-free survival and the method of analysis was intention-to-treat. Randomisation was stopped in December, 2007 because of differences in progression-free and overall survival between the two groups. This trial is registered, reference number ISCRTN45724312. FINDIN …

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.

BACKGROUND: Establishing alternatives to lifelong chemotherapy for patients with advanced pancreatic cancer has been proposed to address che … pilimumab 3 mg/kg intravenously every 4 weeks for four doses. The primary endpoints were safety and progression-free survival at 6 months. Treatment groups were not compared for activity, which was assessed in each group against a clinically meaningful progression-free survival at 6 months of 44% (null hypothesis). Superiority of a treatment regimen could be declared if 6- …

[Predictive significance of microcystic elongated and fragmented (MELF) growth pattern in the prognosis of no specific molecular profile endometrial endometrioid carcinoma].

Objective: To investigate the association between the microcystic, elongated, and fragmented (MELF) growth pattern and the prognosis of no s … ernational Federation of Gynecology and Obstetrics (FIGO) 2023 criteria. The primary endpoints were progression-free survival and disease-specific survival. Patients were divided into MELF (+) and MELF (-) groups based on the presence or absence of the MELF growth pattern, and clinicopathological characteristics were compared between the two groups. Kaplan-Meier survival c …

Sarcopenia, Precardial Adipose Tissue and High Tumor Volume as Outcome Predictors in Surgically Treated Pleural Mesothelioma.

BACKGROUND: We evaluated the prognostic value of Sarcopenia, low precardial adipose-tissue (PAT), and high tumor-volume in the outcome of su … copenia. Additionally, tumor volume as well as PAT were measured. The findings were correlated with progression-free survival and long-term mortality. RESULTS: Two-hundred-seventy-eight PM-patients (252 male; 70.2 ± 9 years) were included. The mean progression-free survival was 18.6 ± 12.2 months, and the mean survival time was 23.3 ± 24 months. Progression was associated …

Pregnancy and Progression of Differentiated Thyroid Cancer: A Propensity Score-Matched Retrospective Cohort Study.

CONTEXT AND OBJECTIVE: Differentiated thyroid cancer (DTC) is very common in women of reproductive age. However, it remains unclear whether … ears, we observed no difference between the pregnant group and the matched nonpregnant group in DTC progression-free survival (hazard ratio [HR] = 0.96; 95% CI, 0.56 to 1.65; P = .895), tumor enlargement-free survival (HR = 0.99; 95% CI, 0.56 to 1.76; P = .969) or lymph node metastasis-free survival (LNM) (HR = 0.67; 95% CI, 0.21 to 2.13; P = .498). The postoperative patho …